Here, the reduced viability, stemness and invasion of mutant ACVR1/wild-type TP53 DMG lines in vitro suggests promise for PRMT5 inhibition in future drug combinations for this most challenging paediatric tumour. Here, ACVR1 is linked to neoplasm.